3 Results Found

Advanced Search

Select all

Results per page

Select all

Review

38 Citations

9,070 Views

45 Pages

The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target

Matthias Niklasch,
Peter Zimmermann and
Michael Nassal

Biomedicines2021, 9(11), 1577;https://doi.org/10.3390/biomedicines9111577

-

29 October 2021

Hepatitis B virus (HBV) is a small enveloped DNA virus which replicates its tiny 3.2 kb genome by reverse transcription inside an icosahedral nucleocapsid, formed by a single ~180 amino acid capsid, or core, protein (Cp). HBV causes chronic hepatitis...

Full Article

Article

19 Citations

4,161 Views

20 Pages

All-Atom MD Simulations of the HBV Capsid Complexed with AT130 Reveal Secondary and Tertiary Structural Changes and Mechanisms of Allostery

Carolina Pérez-Segura,
Boon Chong Goh and
Jodi A. Hadden-Perilla

Viruses2021, 13(4), 564;https://doi.org/10.3390/v13040564

-

26 March 2021

The hepatitis B virus (HBV) capsid is an attractive drug target, relevant to combating viral hepatitis as a major public health concern. Among small molecules known to interfere with capsid assembly, the phenylpropenamides, including AT130, represent...

Full Article

Article

8 Citations

3,248 Views

18 Pages

Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein

Yuan Zheng,
Le Yang,
Lin Yu,
Yuanfei Zhu,
Yang Wu,
Zhijun Zhang,
Tian Xia and
Qiang Deng

Viruses2023, 15(5), 1195;https://doi.org/10.3390/v15051195

-

18 May 2023

Canocapavir is a novel antiviral agent with characteristics of core protein allosteric modulators (CpAMs) that is currently in a phase II clinical trial for treatment of hepatitis B virus (HBV) infection. Herein, we show that Canocapavir prevented th...

Full Article